Nanjing Leads Biolabs and Dianthus Initiate Phase 1 Trial of LBL-047
Nanjing Leads Biolabs Co. and Dianthus Therapeutics announced the first subject has been successfully dosed in the Phase 1 clinical trial of LBL-047, a potential first- and best-in-class anti-BDCA2/TACI bifunctional fusion protein developed by Leads Biolabs. Top-line results in healthy volunteers are anticipated in 2H2.6
